From Pfizer Why do ovaries concentrate lipid nanoparticles and mRNA contained therein so much more effectively than testes?
Is this really applied extermination?
From Pfizer Why do ovaries concentrate lipid nanoparticles and mRNA contained therein so much more effectively than testes?
And does this account for the large disparity in the incidence of Adverse Events and Adverse Events of Special Interest following injection of BNT162b2 in women as opposed to men?
Or are these differences in AEs overall and with respect to the dysfunction in the Reproductive Systems specifically a result of some methodological quirk?
We cannot definitively answer that question at present. For now, we must interpret these data as showing women are at increased risk for Adverse Events from Pfizer’s LNP/mRNA product than are men, both in terms of many or all organ systems but especially with respect to reproductive organ systems and their functions.
Assuming this differential is caused by the disproportionate impact of BNT162b2 on women and their reproductive systems and organs, the implications could be profound.
Appendix 1: Female Reproductive AEs Following Inoculation with BNT162b2
148,874 reproductive organ AEs occurred in women which represents ~16% of the total number of Adverse Events in women. The list below gives the diagnoses reported 10 or more times.
Total AEs N = 923194
Heavy menstrual bleeding 27685
Menstrual disorder 22145
Menstruation irregular 15083
Menstruation delayed 13989
Dysmenorrhea 13904
Intermenstrual bleeding 12424
Amenorrhea 11363
Polymenorrhea 9546
Breast pain 4800
Vaginal hemorrhage 4699
Oligomenorrhea 3437
Hypomenorrhea 2643
Postmenopausal hemorrhage 2456
Abortion spontaneous 1809
Breast swelling 1339
Menstrual discomfort 1199
Premenstrual syndrome 998
Breast tenderness 792
Menometrorrhagia 632
Adnexa uteri pain 609
Premenstrual pain 585
Breast enlargement 483
Vaginal discharge 480
Breast discomfort 443
Mastitis 392
Ovulation pain 347
Endometriosis 337
Menstrual cycle management 308
Anovulatory cycle 273
Uterine pain 270
Abnormal withdrawal bleeding 265
Uterine hemorrhage 231
Vulvovaginal pain 191
Ovulation delayed 181
Premature baby 181
Vulvovaginal mycotic infection 173
Breast cancer 147
Fetal death 147
Fetal growth restriction 124
Vulvovaginal candidiasis 122
Breast cyst 115
Genital hemorrhage 115
Breast edema 113
Abnormal uterine bleeding 100
Pelvic venous thrombosis 98
Labor pain 95
Uterine leiomyoma 91
Polycystic ovaries 82
Breast discharge 71
Vulvovaginal pruritus 71
Breast disorder 68
Uterine contracture during pregnancy 68
Ectopic pregnancy 67
Premature labor 64
Morning sickness 62
Vaginal infection 60
Vulvovaginal discomfort 59
Abortion 58
Premature menopause 58
Vulval ulceration 56
Stillbirth 56
Vulvovaginal dryness 54
Coital bleeding 46
Ovarian cyst rupture 44
Premature delivery 44
Endometrial thickening 42
Genital burning syndrome 42
Adenomyosis 41
Breast abscess 41
Fetal heart rate abnormal 41
Menarche 40
Premenstrual headache 40
Uterine contractions abnormal 40
Breast induration 39
Premature rupture of membranes 37
Uterine polyp 37
Vulvovaginal swelling 37
Abortion induced 36
Uterine inflammation 36
Vulval hemorrhage 34
Pelvic inflammatory disease 33
Pregnancy 32
Pelvic discomfort 30
Premature menarche 27
Premature ovulation 27
Breast hematoma 26
Infertility female 26
Postpartum hemorrhage 26
Uterine disorder 26
Pelvic hemorrhage 25
Noninfective oophoritis 23
Vaginal ulceration 23
Dyspareunia 22
Ovarian disorder 22
Unintended pregnancy 22
Vaginal order 22
Vulvovaginal inflammation 21
Breast cancer 20
Breast disorder female 20
Hemorrhagic ovarian cyst 20
Placental disorder 20
Gestational diabetes 19
Abortion early 19
Endometrial disorder 18
Nipple inflammation 18
Endometrial hyperplasia 18
Ovarian hemorrhage 17
Ovarian failure 16
Vulvovaginal erythema 16
Ovarian vein thrombosis 15
Polymenorrhagia 15
Threatened labor 14
Fibrocystic breast disease 13
Ovarian enlargement 13
Uterine enlargement 13
Cervix hemorrhage uterine 12
Breast atrophy 11
Breast hemorrhage 11
Breast neoplasm 11
Cesarean section 11
Cervical dysplasia 11
Pelvic girdle pain 11
Vaginal disorder 11
Vulval disorder 11
Bartholin’s cyst 10
Decidual cyst 10
Fetal cardiac disorder 10
Fetal growth abnormality 10
Fetal vascular malperfusion 10
Vaginal cyst 10
Small for dates baby 10
Vaginal cyst 10
Appendix 2: Male Reproductive Disorders Following Inoculation with BNT162b2
1,745 reproductive organ AEs were reported in men which represents 0.49% of the total number of Adverse Events in men. AEs list occurred 10 or more times.
Males
Total AEs = 358919
Testicular pain 362
Prostatitis 99
Testicular disorder 90
Epididymitis 73
Orchitis 52
Hematospermia 43
Scrotal pain 40
Penile pain 31
Penis disorder 31
Benign prostatic hypertrophy 26
Penile swelling 25
Scrotal swelling 24
Erection increased 23
Testicular disorder 22
Orchitis noninfective 20
Ejaculation disorder 18
Ejaculation failure 18
Prostatomegaly 18
Priapism 17
Testes discomfort 16
Spontaneous penile erection 15
Penile edema 13
Prostatic disorder 13
Penile hemorrhage 11
Penile erythema 10
Penile vein thrombosis 10
Scrotal erythema 10
Author: Robert W. Chandler, MD, MBA, Team 5
Me: Why does Pfizer want birth control data from vaccines which are supposed to stop Covid?